Re: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer: C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer and L. V. Lacerna. J Urol 2006; 176: 972-978.

Full Abstract

No abstract is available for this article. See 'Journal and Publication Information' further down the page for details that may assist you in locating this article in electronic or hard copy media. The 'Related articles' section also further down the page, where available, may show links to abstracts of articles covering similar topics.

Learn Faster Today Improve your study skills

Author information

Author/s: Gilbert, Scott M (SM); Dunn, Rodney L (RL); Wei, John T (JT);

Journal and publication information

Publication Type: Comment; Letter

Journal: The Journal of urology (J Urol), published in United States. (Language: eng)

Reference: 2007-Apr; vol 177 (issue 4) : pp 1584-5; author reply 1585

Dates: Created 2007/03/26; Completed 2007/04/30;

PMID: 17382782, status: MEDLINE (last retrieval date: 12/26/2008)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

Comments and Corrections

CommentOn: J Urol. 2006 Sep;176(3):972-8; discussion 978. (PMID: 16890673)

External Links for this article (including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Bone Density - drug effects
Bone Density Conservation Agents - therapeutic use
Diphosphonates - therapeutic use
Fractures, Bone - etiology; prevention & control
Gonadotropin-Releasing Hormone - adverse effects; agonists
Humans

Imidazoles - therapeutic use
Male
Orchiectomy - adverse effects
Prostatic Neoplasms - therapy
Risk Factors
Time Factors

Associated Chemicals: Bone Density Conservation Agents (0) ; Diphosphonates (0) ; Imidazoles (0) ; zoledronic acid (118072-93-8) ; Gonadotropin-Releasing Hormone (33515-09-2)

These are the highest related articles currently in the database:

See 100+ related articles.